JP2017517517A5 - - Google Patents

Download PDF

Info

Publication number
JP2017517517A5
JP2017517517A5 JP2016569655A JP2016569655A JP2017517517A5 JP 2017517517 A5 JP2017517517 A5 JP 2017517517A5 JP 2016569655 A JP2016569655 A JP 2016569655A JP 2016569655 A JP2016569655 A JP 2016569655A JP 2017517517 A5 JP2017517517 A5 JP 2017517517A5
Authority
JP
Japan
Prior art keywords
concentration
formulation
chloride salt
peptide
nr2b9c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016569655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017517517A (ja
JP6622222B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/053995 external-priority patent/WO2015181756A1/en
Publication of JP2017517517A publication Critical patent/JP2017517517A/ja
Publication of JP2017517517A5 publication Critical patent/JP2017517517A5/ja
Priority to JP2019210223A priority Critical patent/JP6961661B2/ja
Application granted granted Critical
Publication of JP6622222B2 publication Critical patent/JP6622222B2/ja
Priority to JP2021167771A priority patent/JP7338890B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016569655A 2014-05-28 2015-05-28 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩 Expired - Fee Related JP6622222B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2019210223A JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2021167771A JP7338890B2 (ja) 2014-05-28 2021-10-13 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004142P 2014-05-28 2014-05-28
US62/004,142 2014-05-28
PCT/IB2015/053995 WO2015181756A1 (en) 2014-05-28 2015-05-28 Chloride salt of tat-nr2b9c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019210223A Division JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩

Publications (3)

Publication Number Publication Date
JP2017517517A JP2017517517A (ja) 2017-06-29
JP2017517517A5 true JP2017517517A5 (enExample) 2019-07-25
JP6622222B2 JP6622222B2 (ja) 2019-12-18

Family

ID=54698210

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016569655A Expired - Fee Related JP6622222B2 (ja) 2014-05-28 2015-05-28 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩
JP2023088154A Pending JP2023113751A (ja) 2014-05-28 2023-05-29 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019210223A Expired - Fee Related JP6961661B2 (ja) 2014-05-28 2019-11-21 Ｔａｔ−ＮＲ２Ｂ９ｃの塩化物塩
JP2021167771A Active JP7338890B2 (ja) 2014-05-28 2021-10-13 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩
JP2023088154A Pending JP2023113751A (ja) 2014-05-28 2023-05-29 Ｔａｔ－ＮＲ２Ｂ９ｃの塩化物塩

Country Status (27)

Country Link
US (4) US10206973B2 (enExample)
EP (2) EP3149048B1 (enExample)
JP (4) JP6622222B2 (enExample)
KR (3) KR102605540B1 (enExample)
CN (2) CN106661126B (enExample)
AU (2) AU2015265487B2 (enExample)
BR (1) BR112016027814A2 (enExample)
CA (1) CA2950395C (enExample)
CY (1) CY1122793T1 (enExample)
DK (1) DK3149048T3 (enExample)
ES (2) ES2784500T3 (enExample)
HR (1) HRP20200462T1 (enExample)
HU (1) HUE049074T2 (enExample)
IL (1) IL249252B (enExample)
LT (1) LT3149048T (enExample)
ME (1) ME03790B (enExample)
MX (2) MX374958B (enExample)
PL (1) PL3149048T3 (enExample)
PT (1) PT3149048T (enExample)
RS (1) RS60625B1 (enExample)
RU (2) RU2019138024A (enExample)
SG (2) SG11201609911YA (enExample)
SI (1) SI3149048T1 (enExample)
SM (1) SMT202000307T1 (enExample)
UA (1) UA123820C2 (enExample)
WO (1) WO2015181756A1 (enExample)
ZA (1) ZA201608843B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015181757A1 (en) 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
SMT202000307T1 (it) 2014-05-28 2020-07-08 Nono Inc Sale cloruro di tat-nr2b9c
EP3919507A3 (en) 2015-07-01 2022-01-12 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201620611D0 (en) 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
EP3650460A4 (en) 2017-07-05 2021-03-17 Biocells (Beijing) Biotech Co., Ltd. PHARMACEUTICAL SALT OF A POLYPEPTID AND ITS USES
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CA3166998A1 (en) * 2020-01-09 2021-07-15 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
CN111560050A (zh) * 2020-05-25 2020-08-21 成都圣诺生物制药有限公司 一种Nerinetide的制备方法
AU2022206444A1 (en) 2021-01-08 2023-07-20 Nono Inc. Plasmin-resistant peptides for improved therapeutic index
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
EP4706670A1 (en) 2023-04-26 2026-03-11 Shenzhen Salubris Pharmaceuticals Co., Ltd. Psd-95 domain inhibitor, and preparation method therefor and use thereof
WO2026012336A1 (zh) * 2024-07-08 2026-01-15 福建盛迪医药有限公司 一种psd-95多肽抑制剂的可药用盐及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US9101590B2 (en) * 2005-07-29 2015-08-11 Yale University Defined culture conditions of human embryonic stem cells
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
DK2120987T3 (en) 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
WO2010004003A2 (en) 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
EP2440230B1 (en) * 2009-06-10 2020-11-11 NoNO Inc. Treatment regimes for treatment of neurological disease
WO2012021854A2 (en) * 2010-08-12 2012-02-16 Nono, Inc. Treatment of penetrative injury to the brain
UA114592C2 (uk) * 2010-09-28 2017-07-10 Ноно Інк. Пептид nd2 та спосіб лікування неврологічного захворювання
PL2707014T3 (pl) * 2011-05-13 2015-12-31 Koebenhavns Univ University Of Copenhagen Dimeryczne inhibitory PSD-95 o wysokim powinowactwie i ich zastosowanie w terapii niedokrwiennego uszkodzenia mózgu oraz leczeniu bólu
CN102241745A (zh) * 2011-05-19 2011-11-16 南京医科大学 多肽类似物Tat-HA-NR2B9C及其制备方法和应用
PT2723363T (pt) * 2011-06-24 2018-11-08 Nono Inc Terapia de combinação para isquemia
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
WO2013088382A1 (en) 2011-12-13 2013-06-20 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
KR102166374B1 (ko) 2012-11-28 2020-10-15 노노 인코포레이티드 Tat-nr2b9c의 동결건조된 제형
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
SMT202000307T1 (it) 2014-05-28 2020-07-08 Nono Inc Sale cloruro di tat-nr2b9c
WO2015181757A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger

Similar Documents

Publication Publication Date Title
HRP20200462T1 (hr) Kloridna sol tat-nr2b9c
HRP20200451T1 (hr) Predfuzijski antigeni f iz rsv
MX369534B (es) Composiciones de neisseria meningitidis y sus metodos.
RU2017101667A (ru) Фармацевтические композиции
MX391027B (es) Composiciones de neisseria meningitidis y metodos de la misma.
NZ703120A (en) Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof
JP2015091902A5 (enExample)
JP2013511522A (ja) ダプトマイシン製剤
JP2015527402A5 (enExample)
JP2013511522A5 (enExample)
EA201390400A1 (ru) СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
JP2017521370A5 (enExample)
JP2013508315A5 (enExample)
EA202092926A2 (ru) Лиофилизированные составы, содержащие фактор ix
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
JP2014502275A5 (enExample)
JP2017511816A5 (enExample)
JP2016503058A5 (enExample)
JP2019533679A5 (enExample)
SI2968442T1 (en) New stable pentadecapeptide salts, a process for their preparation, their use in the manufacture of pharmaceutical preparations and their use in therapy
MX2016012870A (es) Formulaciones de factor viii estables con bajo tenor de azucar - glicina.
JP2015518873A5 (enExample)
MX2015009141A (es) Formulaciones de albu-bche, preparacion y usos de las mismas.
MX2018007413A (es) Formulaciones de vacuna contra rotavirus termicamente estable y metodos de uso de la misma.